Authors
Koyama, Satoshi Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine Researchers DB
Fujiwara, Kazunori Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine Researchers DB KAKEN
Morisaki, Tsuyoshi Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine
Fujii, Taihei Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine / Center for Head and Neck Surgery, Kusatsu General Hospital
Nakamura, Yosuke Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine Researchers DB KAKEN
Fukuhara, Takahiro Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine Researchers DB KAKEN
Takeuchi, Hiromi Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine Researchers DB KAKEN
Keywords
Basaloid squamous cell carcinoma
Cetuximab
Head and neck
Metastasis
Chemotherapy
Abstract
Basaloid squamous cell carcinoma (BSCC), a histologically distinctive variant of squamous cell carcinoma comprising basal cell carcinoma and squamous cell carcinoma, is aggressive and shows a poor prognosis because of frequent lymph node invasion and distant metastases. To date few articles regarding chemotherapy for metastatic disease have been reported, thus feasible chemotherapy is not well established. Cetuximab is a monoclonal antibody for epithelial growth factor receptor (EGFR), which has great efficacy for head and neck squamous cell carcinoma due to EGFR signaling pathway blockage. Because BSCC also highly expresses EGFR, cetuximab may be effective for BSCC. We report here a first case of recurrent BSCC in the ethmoid sinus with intracranial extension treated with cetuximab-based chemotherapy, which revealed great response in a 40-year-old man. Positron emission tomography (PET) revealed no lymph node or distant metastasis. The patient underwent chemoradiotherapy 66 Gy in 33 fractions with triweekly 100 mg/m2 cisplatin. However, 12 weeks after treatment completion PET revealed a residual tumor at the primary cancer site. Combination therapy with weekly paclitaxel and cetuximab was started, and complete response was observed 2 months from treatment initiation. The patient has maintained complete response for 32 months, and no tumor regrowth has been observed.
Publisher
Elsevier B.V.
Content Type
Journal Article
Link
ISSN
03858146
Journal Title
Auris Nasus Larynx
Current Journal Title
Auris Nasus Larynx
Volume
48
Issue
6
Start Page
1189
End Page
1192
Published Date
2021-12
Publisher-DOI
Text Version
Author
Rights
© 2020 Oto-Rhino-Laryngological Society of Japan Inc. Published by Elsevier B.V. All rights reserved.
Citation
Koyama, Satoshi. Fujiwara, Kazunori. Morisaki, Tsuyoshi. et al. Cetuximab and paclitaxel combination therapy for recurrent basaloid squamous cell carcinoma in the ethmoid sinus. Auris Nasus Larynx. 48(6), 1189-1192. 2020-07-16.
Department
Faculty of Medicine/Graduate School of Medical Sciences/University Hospital
Language
English
pii
S0385-8146(20)30159-0